MPN Research Foundation

06/04/2026

We’re grateful to the UChicago Medicine for welcoming the MPN Research Foundation team into the Drazer Group lab and HIM Lab following the 2026 MPN Roundtable™.

Seeing early-stage research up close is a powerful reminder of where progress in myeloproliferative neoplasms (MPNs) starts and how it gets from bench to bedside: collaboration across the entire MPN community.

Thank you to the University of Chicago team for welcoming us and for giving our team a meaningful look at the collaborative effort behind progress in MPNs.

👉 Join the effort to advance MPN research: https://goto.mpnresearchfoundation.org/4pIYQrn

06/01/2026

Over the past months, we’ve been working to implement some improvements to the MPN PROGRESSion Registry® enrollment and portal systems. Scroll through the images to learn about the updates that have launched!

This initial round of enhancements is just a start. We are committed to making the Registry the best possible experience for patients during enrollment, and throughout long-term participation. So, we’ll be working to improve the MPN PROGRESSion Registry® system on an ongoing basis. Let us know how we are doing.

Already a participant? Log in to your portal to see some of the changes.

Not yet enrolled? Join us! Learn more and register today: https://f.mtr.cool/hppxdpxbez

05/30/2026

One early investment can create a lasting ripple effect.

Since 2007, MPN Research Foundation has championed the Myeloproliferative Neoplasm Research Consortium, a collaborative network now spanning 17 institutions. An essential part of this work is the MPN‑RC Tissue Bank, one of the world’s largest collections of myeloproliferative neoplasm (MPN) patient blood and bone marrow samples.

These real‑world specimens allow researchers to study disease progression, biomarkers, and treatment response in ways laboratory models alone cannot. Nearly 2,000 patient samples are already advancing discovery worldwide.

This is what foundational funding makes possible. There is still time to support the infrastructure that allows research to move faster and further.

Invest in research: https://f.mtr.cool/oswwaaquob

05/28/2026

For people living with myeloproliferative neoplasms (MPNs), progress means more than scientific breakthroughs; it means getting better treatments to patients sooner. As the MPN community works to modernize how clinical trial success is measured, the 2026 MPN Roundtable™ highlighted important lessons from another blood cancer that has made real progress in this area: multiple myeloma.

In his keynote, Dr. C. Ola Landgren, MD, PhD, shared how years of collaboration helped the myeloma field agree on meaningful markers of treatment response, including minimal residual disease, or MRD, a way of detecting very small amounts of remaining cancer after treatment.

What can MPN research learn from this path?
• Earlier answers can lead to faster progress. In myeloma, MRD helped researchers understand sooner whether a treatment was working.
• Shared standards build trust. Agreeing on how and when to measure response made results more reliable across studies.
• Working together makes the difference. Advances came from researchers, doctors, industry, and regulators working toward a common goal.

This is why convening the community matters. At MPN Research Foundation, we bring researchers, clinicians, patients, caregivers, and industry together at events such as our annual MPN Roundtable to align on unmet needs and move the field forward together.

Stay connected and be part of what comes next: https://f.mtr.cool/mshgmqmeov

05/27/2026

Scientific research shapes progress in myeloproliferative neoplasm (MPN) care but scientific presentations aren’t always easy to follow.

Join us for MPN Pathways: Empowered Voices in Research: Patients' and Caregivers’ Guide to Scientific Presentations.

Date: June 18
Time: 5–6pm CT
Location: Virtual

Free | Recording available

Featuring:
• Amielle Moreno, PhD, Scientific Content Manager, MPN Research Foundation
• Tyler Parsons, PhD, MPN researcher and member of the MPN Research Foundation Patient Impact Council

Together, they will break down how scientific presentations work and how to find the key message, even when the details feel complex.

Register today: https://f.mtr.cool/gpvwtanhtv

05/26/2026

We are looking forward to this webinar and hope you can join us!

There’s still time to register for the next MPN United global webinar.

Join us for an educational session focused on how research is helping improve understanding of myeloproliferative neoplasms (MPNs) and guide future treatment ideas.

The Science of CALR: From Mutation Discovery to Emerging Therapeutic Strategies
🗓 Wednesday, June 3, 2026
🕘 9:00 – 10:30 AM CT / 4:00 – 5:30 PM CEST
🎙 Speaker: Dr. Robert Kralovics

🌍 Live translated captions available
🎥 Recording provided to all registrants

✨ The session will also include a Best Practice Spotlight featuring MPN Voice and Vivre avec une NMP, sharing their experience delivering a multi language, international webinar for parents of children and adolescents with MPNs.

🔗 Reserve your spot: https://us02web.zoom.us/webinar/register/WN_gC_ZDkpfToyy6HTXCDVmPA

05/26/2026

Why do some people develop myeloproliferative neoplasms (MPNs), while others never do?

Research shows MPNs often begin long before diagnosis, when a mutation appears in a blood stem cell and slowly grows over time. What we’re learning is reshaping how these diseases are understood — and why continued research matters.

• 3 key gene mutations: About 90–95% of patients have a mutation in JAK2, CALR, or MPL that cause blood stem cells to stay “switched on.”
• Mutations before symptoms: These mutations can arise early in life and expand quietly for decades before symptoms appear.
• Genes don’t act alone: Mutated cell growth may depend on inherited biology, the bone marrow environment, inflammation, and possibly lifestyle.

We’re energized by what we’re seeing in our pipeline. This year, 53 eligible teams applied to the 2026 MPN Challenge™! Some of these projects will push forward on unanswered questions around genetic drivers of disease like MPL. Your support makes this progress possible.

Invest in research: https://f.mtr.cool/zsawatnqzn

Learn more from Dr. Jyoti Nangalia: https://f.mtr.cool/syfsnubxgf

05/25/2026

It starts with science, but it is strengthened by the perspectives of those living with these diseases.

At this year’s MPN Roundtable™, conversations focused on a critical topic in myeloproliferative neoplasms (MPNs): clinical endpoints, and how we define and measure progress in research.

By bringing researchers, clinicians, biopharmaceutical industry partners, patients and caregivers together, we help ensure the science reflects what matters most: advancing understanding and shaping future outcomes.

This is what makes MPN Research Foundation’s approach unique: patient-informed research that helps move the field forward, together.

👉 Join the effort to advance MPN research https://f.mtr.cool/xayamlhrky

Thank you to our sponsors that help make this event possible: Bristol Myers Squibb, Calytrix, GSK, Incyte, Italfarmaco, KartosTherapeutics, Karyopharm Therapeutics, MerckInvents, Novartis, PharmaEssentia, Sobi, Sumitomo Pharma Oncology, Takeda

05/22/2026

New treatments usually start with learning more about the disease itself. This early work is called basic research or pre‑clinical research, and it’s where researchers learn how myeloproliferative neoplasms (MPNs) begin and change over time.

From the very start, MPN Research Foundation focused on this kind of science. Why? Because understanding the biology behind essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF) is what makes smarter studies and better treatment options possible later on.

What that commitment has enabled:
• The Foundation has awarded more than $20 million in MPN research funding to date.
• We have over $1 million in planned investments this year alone.

Basic research doesn’t always make popular headlines, but it quietly shapes the breakthroughs that do. If you care about progress, you know “basic” doesn’t mean simple. It means building the foundation patients depend on.

Invest in research: https://f.mtr.cool/ffcsvhbukm

05/21/2026

MPN Research Foundation is sharing an opportunity from The Harris Poll, an independent polling and insights firm, to learn more about the lived experiences of people diagnosed with polycythemia vera (PV) and live in the US.

This confidential, online survey takes approximately 20 minutes and invites individuals with PV to share their perspectives on the physical, emotional, and practical impact of living with the disease — as well as the support and resources that matter most. Responses are kept strictly confidential and reported only in total to protect participant privacy.

Understanding the real‑world experience of people living with PV is essential for informing future research, improving study design, and ensuring that patient priorities remain central.

Please note: the survey must be completed in one sitting, as responses are saved only upon final submission.

Take the survey: https://f.mtr.cool/eyknjytvuk

Questions? Contact [email protected]

MPN Research Foundation does not endorse any specific treatments or trials. We raise awareness of relevant research opportunities while remaining neutral and mission‑focused.